Unknown

Dataset Information

0

Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.


ABSTRACT: Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.

SUBMITTER: Nyland SB 

PROVIDER: S-EPMC3312981 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.

Nyland Susan Bell SB   Krissinger Daniel J DJ   Clemente Michael J MJ   Irby Rosalyn B RB   Baab Kendall Thomas KT   Jarbadan Nancy Ruth NR   Sokol Lubomir L   Schaefer Eric E   Liao Jason J   Cuthbertson David D   Epling-Burnette Pearlie P   Paquette Ronald R   List Alan F AF   Maciejewski Jaroslaw P JP   Loughran Thomas P TP  

Leukemia research 20120302 5


Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera  ...[more]

Similar Datasets

| S-EPMC7546795 | biostudies-literature
| S-EPMC8550969 | biostudies-literature
| S-EPMC7495826 | biostudies-literature
| S-EPMC4215311 | biostudies-literature
| S-EPMC5529684 | biostudies-literature
| S-EPMC8672449 | biostudies-literature
| S-EPMC6023248 | biostudies-literature
| S-EPMC9631592 | biostudies-literature
| S-EPMC6590537 | biostudies-literature
| S-EPMC3798994 | biostudies-literature